Trials / Unknown
UnknownNCT04550806
Glycated Albumin Combined With Body Composition for Gestational Diabetes Mellitus Prediction
The Predictive Ability of Glycated Albumin Combined With Body Composition for Gestational Diabetes Mellitus Diagnosis
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- Female
- Age
- 22 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is going to investigate the predictive ability of glycated albumin combined with body composition, including body weight, BMI, fat free mass and fat mass for gestational diabetes mellitus (GDM) diagnosis.
Detailed description
The prevalence of GDM is increasing all over the world. It has bad influence for both pregnant women and fetus. Early treatment is useful for GDM prevention. Therefore early screening is important for healthcare doctors to detect the potential patients. Glycated albumin (GA) is an optimal index for blood glucose evaluation compared to HbA1c, however it may be influenced by body weight and composition. The investigators are going to investigate the predictive ability of glycated albumin combined with body composition, including body weight, BMI, fat free mass and fat mass for gestational diabetes mellitus (GDM) diagnosis. This study recruit pregnant women before 12 weeks of their pregnant age and test GA level and body composition via bioelectrical impedance analysis. During 24-28 weeks of pregnant age, all participants will do the glucose tolerant test for GDM diagnosis.
Conditions
Timeline
- Start date
- 2020-10-01
- Primary completion
- 2021-06-01
- Completion
- 2021-07-01
- First posted
- 2020-09-16
- Last updated
- 2020-10-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04550806. Inclusion in this directory is not an endorsement.